Cargando…

Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial

BACKGROUND: Patients with cirrhosis and portal hypertension face a high risk of complications. Besides their anti-inflammatory and antifibrotic effects, statins may reduce portal pressure and thus the risk of complications and mortality. We aimed to investigate the effects of atorvastatin on hospita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kronborg, Thit M., Schierwagen, Robert, Trošt, Kajetan, Gao, Qian, Moritz, Thomas, Bendtsen, Flemming, Gantzel, Rasmus H., Andersen, Mette L., Teisner, Ane S., Grønbæk, Henning, Hobolth, Lise, Møller, Søren, Trebicka, Jonel, Kimer, Nina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697620/ http://dx.doi.org/10.1097/HC9.0000000000000332

Ejemplares similares

Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study
por: Kronborg, Thit Mynster, et al.
Publicado: (2021)

Markers of inflammation predict survival in newly diagnosed cirrhosis: a prospective registry study
por: Mynster Kronborg, Thit, et al.
Publicado: (2023)

Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
por: Kimer, Nina, et al.
Publicado: (2020)

Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
por: Nielsen, Marlene Christina, et al.
Publicado: (2020)

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
por: Kimer, Nina, et al.
Publicado: (2018)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial
por: Kimer, Nina, et al.
Publicado: (2022)

Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?
por: Nabilou, Puria, et al.
Publicado: (2022)

Tunneled Peritoneal Catheter for Refractory Ascites in Cirrhosis: A Randomized Case-Series
por: Kimer, Nina, et al.
Publicado: (2020)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

Suboptimal diagnostic accuracy of ultrasound and CT for compensated cirrhosis: Evidence from prospective cohort studies
por: Hetland, Liv E., et al.
Publicado: (2023)

Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: A systematic review
por: O’Connell, Malene Barfod, et al.
Publicado: (2023)

Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension
por: Trebicka, Jonel, et al.
Publicado: (2013)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis
por: Schierwagen, Robert, et al.
Publicado: (2020)

Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2021)

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
por: Iwakiri, Yasuko, et al.
Publicado: (2021)

Future therapy of portal hypertension in liver cirrhosis – a guess
por: Sauerbruch, Tilman, et al.
Publicado: (2014)

PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension
por: Jansen, Christian, et al.
Publicado: (2014)

Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
por: Sauerbruch, Tilman, et al.
Publicado: (2021)

Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis
por: Alvarez-Silva, Camila, et al.
Publicado: (2019)

Portal vein thrombosis in patients with cirrhosis
por: von Köckritz, Leona, et al.
Publicado: (2017)

Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2022)

Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments
por: Herath, Chandana B., et al.
Publicado: (2022)

Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis
por: Benz, Fabian, et al.
Publicado: (2020)

Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS
por: Queck, Alexander, et al.
Publicado: (2020)

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2021)

Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study
por: Krag, Aleksander, et al.
Publicado: (2014)

Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis
por: Klein, Sabine, et al.
Publicado: (2015)

Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2022)

Extracellular Matrix Remodeling in Chronic Liver Disease
por: Ortiz, Cristina, et al.
Publicado: (2021)

Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation
por: Casey, Stephen, et al.
Publicado: (2019)

Trust is good, control is better: technical considerations in blood microbiome analysis
por: Schierwagen, Robert, et al.
Publicado: (2020)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis
por: Queck, Alexander, et al.
Publicado: (2019)

Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure
por: Blaya, Delia, et al.
Publicado: (2021)

Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats
por: Schierwagen, Robert, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cndshngmmh6frj06gbmj250th4